Varicella-Zoster virus and herpes simplex virus 1 differentially modulate NKG2D ligand expression during productive infection

Journal of Virology

Volumn 89, Issue 15, 2015, Pages 7932-7943

  Campbell, Tessa M ^a   McSharry, Brian P ^a   Steain, Megan ^a   Slobedman, Barry ^a   Abendroth, Allison ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN MICA; PROTEIN ULBP2; PROTEIN ULBP3; UNCLASSIFIED DRUG; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HLA ANTIGEN CLASS 1; KLRK1 PROTEIN, HUMAN; LIGAND; MHC CLASS I-RELATED CHAIN A; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; SIGNAL PEPTIDE; ULBP2 PROTEIN, HUMAN; ULBP3 PROTEIN, HUMAN;

ARTICLE; CELL SURFACE; CONTROLLED STUDY; EMBRYO; EPITHELIUM CELL; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IMMUNE EVASION; KIDNEY CELL; LYMPHOCYTE ACTIVATION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN FIBROBLAST; UPREGULATION; VARICELLA ZOSTER VIRUS; VERO CELL LINE; CELL LINE; GENETICS; HERPES SIMPLEX; HERPES ZOSTER; IMMUNOLOGY; PHYSIOLOGY; VIROLOGY;

HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 3;

CELL LINE; GPI-LINKED PROTEINS; HERPES SIMPLEX; HERPES ZOSTER; HERPESVIRUS 1, HUMAN; HERPESVIRUS 3, HUMAN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KILLER CELLS, NATURAL; LIGANDS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K;

EID: 84937710700     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00292-15     Document Type: Article

References (63)

1. Baines JD, Pellett PE. 2007. Genetic comparison of human alphaherpesvirus genomes, p 61-69. In Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K (ed), Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge University Press, Cambridge, United Kingdom.
2. Kinchington PR, Leger AJ, Guedon JM, Hendricks RL. 2012. Herpes simplex virus and varicella zoster virus, the house guests who never leave. Herpesviridae 3:5. http://dx.doi.org/10.1186/2042-4280-3-5.
3. Steain M, Slobedman B, Abendroth A. 2012. The host immune response to varicella zoster virus. Future Virol 7:1205-1220. http://dx.doi.org/10.2217/fvl.12.116.
4. Egan KP, Wu S, Wigdahl B, Jennings SR. 2013. Immunological control of herpes simplex virus infections. J Neurovirol 19:328-345. http://dx.doi.org/10.1007/s13365-013-0189-3.
5. Biron CA, Byron KS, Sullivan JL. 1989. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 320:1731-1735. http://dx.doi.org/10.1056/NEJM198906293202605.
6. de Vries E, Koene HR, Vossen JM, Gratama JW, von dem Borne AE, Waaijer JL, Haraldsson A, de Haas M, van Tol MJ. 1996. Identification of an unusual Fc gamma receptor IIIa (CD16) on natural killer cells in a patient with recurrent infections. Blood 88:3022-3027.
7. Jawahar S, Moody C, Chan M, Finberg R, Geha R, Chatila T. 1996. Natural killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA (CD16-II). Clin Exp Immunol 103:408-413.
8. Wendland T, Herren S, Yawalkar N, Cerny A, Pichler WJ. 2000. Strong alpha beta and gamma delta TCR response in a patient with disseminated Mycobacterium avium infection and lack of NK cells and monocytopenia. Immunol Lett 72:75-82. http://dx.doi.org/10.1016/S0165-2478(00)00169-3.
9. Orange JS. 2002. Human natural killer cell deficiencies and susceptibility to infection. Microbes Infect 4:1545-1558. http://dx.doi.org/10.1016/S1286-4579(02)00038-2.
10. Etzioni A, Eidenschenk C, Katz R, Beck R, Casanova JL, Pollack S. 2005. Fatal varicella associated with selective natural killer cell deficiency. J Pediatr 146:423-425. http://dx.doi.org/10.1016/j.jpeds.2004.11.022.
11. Notarangelo LD, Mazzolari E. 2006. Natural killer cell deficiencies and severe varicella infection. J Pediatr 148:563-564. http://dx.doi.org/10.1016/j.jpeds.2005.06.028.
12. Orange JS. 2013. Natural killer cell deficiency. J Allergy Clin Immunol 132:515-525. http://dx.doi.org/10.1016/j.jaci.2013.07.020.
13. Hill A, Jugovic P, York I, Russ G, Bennink J, Yewdell J, Ploegh H, Johnson D. 1995. Herpes simplex virus turns off the TAP to evade host immunity. Nature 375:411-415. http://dx.doi.org/10.1038/375411a0.
14. Cohen JI. 1998. Infection of cells with varicella-zoster virus downregulates surface expression of class I major histocompatibility complex antigens. J Infect Dis 177:1390-1393. http://dx.doi.org/10.1086/517821.
15. Abendroth A, Lin I, Slobedman B, Ploegh H, Arvin AM. 2001. Varicellazoster virus retains major histocompatibility complex class I proteins in the Golgi compartment of infected cells. J Virol 75:4878-4888. http://dx.doi.org/10.1128/JVI.75.10.4878-4888.2001.
16. Eisfeld AJ, Yee MB, Erazo A, Abendroth A, Kinchington PR. 2007. Downregulation of class I major histocompatibility complex surface expression by varicella-zoster virus involves open reading frame 66 protein kinase-dependent and-independent mechanisms. J Virol 81:9034-9049. http://dx.doi.org/10.1128/JVI.00711-07.
17. Imai T, Koyanagi N, Ogawa R, Shindo K, Suenaga T, Sato A, Arii J, Kato A, Kiyono H, Arase H, Kawaguchi Y. 2013. Us3 kinase encoded by herpes simplex virus 1 mediates downregulation of cell surface major histocompatibility complex class I and evasion of CD8+ T cells. PLoS One 8:e72050. http://dx.doi.org/10.1371/journal.pone.0072050.
18. Ljunggren HG, Kärre K. 1990. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 11:237-244. http://dx.doi.org/10.1016/0167-5699(90)90097-S.
19. Lanier LL. 2008. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 9:495-502. http://dx.doi.org/10.1038/ni1581.
20. Ito M, Bandyopadhyay S, Matsumoto-Kobayashi M, Clark SC, Miller D, Starr SE. 1986. Interleukin 2 enhances natural killing of varicellazoster virus-infected targets. Clin Exp Immunol 65:182-189.
21. Tilden AB, Cauda R, Grossi CE, Balch CM, Lakeman AD, Whitley RJ. 1986. Demonstration of NK cell-mediated lysis of varicella-zoster virus (VZV)-infected cells: characterization of the effector cells. J Immunol 136: 4243-4248.
22. Fitzgerald PA, Mendelsohn M, Lopez C. 1985. Human natural killer cells limit replication of herpes simplex virus type 1 in vitro. J Immunol 134: 2666-2672.
23. Chisholm SE, Howard K, Gomez MV, Reyburn HT. 2007. Expression of ICP0 is sufficient to trigger natural killer cell recognition of herpes simplex virus-infected cells by natural cytotoxicity receptors. J Infect Dis 195: 1160-1168. http://dx.doi.org/10.1086/512862.
24. Schepis D, D'Amato M, Studahl M, Bergström T, Kärre K, Berg L. 2009. Herpes simplex virus infection downmodulates NKG2D ligand expression. Scand J Immunol 69:429-436. http://dx.doi.org/10.1111/j.1365-3083.2009.02241.x.
25. Odom CI, Gaston DC, Markert JM, Cassady KA. 2012. Human herpesviridae methods of natural killer cell evasion. Adv Virol 2012:359869. http://dx.doi.org/10.1155/2012/359869.
26. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T. 1999. Activation of NK cells and T cells by NKG2D, a receptor for stressinducible MICA. Science 285:727-729. http://dx.doi.org/10.1126/science.285.5428.727.
27. Gonzalez S, Groh V, Spies T. 2006. Immunobiology of human NKG2D and its ligands. Curr Top Microbiol Immunol 298:121-138. http://dx.doi.org/10.1007/3-540-27743-9_6.
28. Eagle RA, Trowsdale J. 2007. Promiscuity and the single receptor: NKG2D. Nat Rev Immunol 7:737-744. http://dx.doi.org/10.1038/nri2144.
29. Fernandez-Messina L, Reyburn HT, Vales-Gomez M. 2012. Human NKG2D-ligands: cell biology strategies to ensure immune recognition. Front Immunol 3:299. http://dx.doi.org/10.3389/fimmu.2012.00299.
30. Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. 2013. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 31:413-441. http://dx.doi.org/10.1146/annurev-immunol-032712-095951.
31. Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T. 1996. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA 93:12445-12450. http://dx.doi.org/10.1073/pnas.93.22.12445.
32. Cosman D, Müllberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, Kubin M, Chalupny NJ. 2001. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14:123-133. http://dx.doi.org/10.1016/S1074-7613(01)00095-4.
33. Chalupny NJ, Rein-Weston A, Dosch S, Cosman D. 2006. Downregulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142. Biochem Biophys Res Commun 346:175-181. http://dx.doi.org/10.1016/j.bbrc.2006.05.092.
34. Stern-Ginossar N, Elefant N, Zimmermann A, Wolf DG, Saleh N, Biton M, Horwitz E, Prokocimer Z, Prichard M, Hahn G, Goldman-Wohl D, Greenfield C, Yagel S, Hengel H, Altuvia Y, Margalit H, Mandelboim O. 2007. Host immune system gene targeting by a viral miRNA. Science 317: 376-381. http://dx.doi.org/10.1126/science.1140956.
35. Eagle RA, Traherne JA, Hair JR, Jafferji I, Trowsdale J. 2009. ULBP6/RAET1L is an additional human NKG2D ligand. Eur J Immunol 39:3207-3216. http://dx.doi.org/10.1002/eji.200939502.
36. Bennett NJ, Ashiru O, Morgan FJ, Pang Y, Okecha G, Eagle RA, Trowsdale J, Sissons JG, Wills MR. 2010. Intracellular sequestration of the NKG2D ligand ULBP3 by human cytomegalovirus. J Immunol 185: 1093-1102. http://dx.doi.org/10.4049/jimmunol.1000789.
37. Fielding CA, Aicheler R, Stanton RJ, Wang EC, Han S, Seirafian S, Davies J, McSharry BP, Weekes MP, Antrobus PR, Prod'homme V, Blanchet FP, Sugrue D, Cuff S, Roberts D, Davison AJ, Lehner PJ, Wilkinson GW, Tomasec P. 2014. Two novel human cytomegalovirus NK cell evasion functions target MICA for lysosomal degradation. PLoS Pathog 10:e1004058. http://dx.doi.org/10.1371/journal.ppat.1004058.
38. Schneider CL, Hudson AW. 2011. The human herpesvirus-7 (HHV-7) U21 immunoevasin subverts NK-mediated cytoxicity through modulation of MICA and MICB. PLoS Pathog 7:e1002362. http://dx.doi.org/10.1371/journal.ppat.1002362.
39. Thomas M, Boname JM, Field S, Nejentsev S, Salio M, Cerundolo V, Wills M, Lehner PJ. 2008. Down-regulation of NKG2D and NKp80 ligands by Kaposi's sarcoma-associated herpesvirus K5 protects against NK cell cytotoxicity. Proc Natl Acad Sci USA 105:1656-1661. http://dx.doi.org/10.1073/pnas.0707883105.
40. Nachmani D, Stern-Ginossar N, Sarid R, Mandelboim O. 2009. Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. Cell Host Microbe 5:376-385. http://dx.doi.org/10.1016/j.chom.2009.03.003.
41. Moffat JF, Zerboni L, Kinchington PR, Grose C, Kaneshima H, Arvin AM. 1998. Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse. J Virol 72:965-974.
42. Ejercito PM, Kieff ED, Roizman B. 1968. Characterization of herpes simplex virus strains differing in their effects on social behaviour of infected cells. J Gen Virol 2:357-364. http://dx.doi.org/10.1099/0022-1317-2-3-357.
43. Halford WP, Schaffer PA. 2001. ICP0 is required for efficient reactivation of herpes simplex virus type 1 from neuronal latency. J Virol 75:3240-3249. http://dx.doi.org/10.1128/JVI.75.7.3240-3249.2001.
44. Alter G, Malenfant JM, Altfeld M. 2004. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 294:15-22. http://dx.doi.org/10.1016/j.jim.2004.08.008.
45. Weller TH. 1953. Serial propagation in vitro of agents producing inclusion bodies derived from varicella and herpes zoster. Proc Soc Exp Biol Med 83:340-346. http://dx.doi.org/10.3181/00379727-83-20354.
46. Schmidt-Chanasit J, Bleymehl K, Rabenau HF, Ulrich RG, Cinatl J, Jr, Doerr HW. 2008. In vitro replication of varicella-zoster virus in human retinal pigment epithelial cells. J Clin Microbiol 46:2122-2124. http://dx.doi.org/10.1128/JCM.00122-08.
47. Cerboni C, Mousavi-Jazi M, Linde A, Soderstrom K, Brytting M, Wahren B, Kärre K, Carbone E. 2000. Human cytomegalovirus straindependent changes in NK cell recognition of infected fibroblasts. J Immunol 164:4775-4782. http://dx.doi.org/10.4049/jimmunol.164.9.4775.
48. Wilkinson GW, Tomasec P, Stanton RJ, Armstrong M, Prod'homme V, Aicheler R, McSharry BP, Rickards CR, Cochrane D, Llewellyn-Lacey S, Wang EC, Griffin CA, Davison AJ. 2008. Modulation of natural killer cells by human cytomegalovirus. J Clin Virol 41:206-212. http://dx.doi.org/10.1016/j.jcv.2007.10.027.
49. McSharry BP, Burgert H-G, Owen DP, Stanton RJ, Prod'homme V, Sester M, Koebernick K, Groh V, Spies T, Cox S, Little A-M, Wang ECY, Tomasec P, Wilkinson GWG. 2008. Adenovirus E3/19K promotes evasion of NK cell recognition by intracellular sequestration of the NKG2D ligands major histocompatibility complex class I chain-related proteins A and B. J Virol 82:4585-4594. http://dx.doi.org/10.1128/JVI.02251-07.
50. Venkataraman GM, Suciu D, Groh V, Boss JM, Spies T. 2007. Promoter region architecture and transcriptional regulation of the genes for the MHC class I-related chain A and B ligands of NKG2D. J Immunol 178: 961-969. http://dx.doi.org/10.4049/jimmunol.178.2.961.
51. Ohgitani E, Kobayashi K, Takeshita K, Imanishi J. 1998. Induced expression and localization to nuclear-inclusion bodies of hsp70 in varicella-zoster virus-infected human diploid fibroblasts. Microbiol Immunol 42:755-760. http://dx.doi.org/10.1111/j.1348-0421.1998.tb02349.x.
52. Steinle A, Li P, Morris DL, Groh V, Lanier LL, Strong RK, Spies T. 2001. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Immunogenetics 53:279-287. http://dx.doi.org/10.1007/s002510100325.
53. Choy MK, Phipps ME. 2010. MICA polymorphism: biology and importance in immunity and disease. Trends Mol Med 16:97-106. http://dx.doi.org/10.1016/j.molmed.2010.01.002.
54. Gao X, Single RM, Karacki P, Marti D, O'Brien SJ, Carrington M. 2006. Diversity of MICA and linkage disequilibrium with HLA-B in two North American populations. Hum Immunol 67:152-158. http://dx.doi.org/10.1016/j.humimm.2006.02.009.
55. Wenda S, Fae I, Sanchez-Mazas A, Nunes JM, Mayr WR, Fischer GF. 2013. The distribution of MICA alleles in an Austrian population: evidence for increasing polymorphism. Hum Immunol 74:1295-1299. http://dx.doi.org/10.1016/j.humimm.2013.06.013.
56. Ashiru O, Bennett NJ, Boyle LH, Thomas M, Trowsdale J, Wills MR. 2009. NKG2D ligand MICA is retained in the cis-Golgi apparatus by human cytomegalovirus protein UL142. J Virol 83:12345-12354. http://dx.doi.org/10.1128/JVI.01175-09.
57. Zou Y, Bresnahan W, Taylor RT, Stastny P. 2005. Effect of human cytomegalovirus on expression of MHC class I-related chains A. J Immunol 174:3098-3104. http://dx.doi.org/10.4049/jimmunol.174.5.3098.
58. Seidel E, Le VT, Bar-On Y, Tsukerman P, Enk J, Yamin R, Stein N, Schmiedel D, Oiknine Djian E, Weisblum Y, Tirosh B, Stastny P, Wolf DG, Hengel H, Mandelboim O. 12 February 2015. Dynamic co-evolution of host and pathogen: HCMV downregulates the prevalent allele MICA*008 to escape elimination by NK cells. Cell Rep http://dx.doi.org/10.1016/j.celrep.2015.01.029.
59. Hayashi K, Kawauchi M, Nakai C, Sankawa U, Seto H, Hayashi T. 2001. Characterization of inhibitory action of concanamycins against herpes simplex virus. Antivir Chem Chemother 12:51-59. http://dx.doi.org/10.1177/095632020101200103.
60. La Frazia S, Amici C, Santoro MG. 2006. Antiviral activity of proteasome inhibitors in herpes simplex virus-1 infection: role of nuclear factorkappaB. Antivir Ther 11:995-1004.
61. Slavuljica I, Krmpotic A, Jonjic S. 2011. Manipulation of NKG2D ligands by cytomegaloviruses: impact on innate and adaptive immune response. Front Immunol 2:85. http://dx.doi.org/10.3389/fimmu.2011.00085.
62. Müller S, Zocher G, Steinle A, Stehle T. 2010. Structure of the HCMV UL16-MICB complex elucidates select binding of a viral immunoevasin to diverse NKG2D ligands. PLoS Pathog 6:e1000723. http://dx.doi.org/10.1371/journal.ppat.1000723.
63. Grauwet K, Cantoni C, Parodi M, De Maria A, Devriendt B, Pende D, Moretta L, Vitale M, Favoreel HW. 2014. Modulation of CD112 by the alphaherpesvirus gD protein suppresses DNAM-1-dependent NK cellmediated lysis of infected cells. Proc Natl Acad Sci USA 111:16118-16123. http://dx.doi.org/10.1073/pnas.1409485111.